SBIR/STTR Research Award
SPECKLE-FREE ATTENUATION ULTRASOUND PROSTATE IMAGING
Award amount
$99,972Program and phase
SBIR · Phase IAward year
2002Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Imperium, Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
Description (provided by applicant): Imperium Inc. proposes to develop a
speckle-free ultrasound camera to image normal and abnormal tissue structures
in the prostate. The system will utilize a unique C-scan reflection mode
imaging modality based our patented ultrasound technology. The basis of the
technology is a fully populated, microelectronic detector array of
piezoelectric pixels and read-out circuitry designed to generate C-scan images
at TV frame rates.
In this project, we will investigate the feasibility of employing a reflection
mode ultrasound modality in imaging the prostate. These studies will further
our efforts in future projects to perform diagnostic imaging of human soft
tissues including breast, connective tissues, vascular diseases, child and
infant cartilage for study of bone formation. This system is capable of imaging
soft tissue conditions and medical operations that require clear, speckle-free,
non-distorted, real time imaging. The proposed imaging modality is low cost and
free of ionizing radiation.
Following the successful completion of this study we will fabricate a prostate
probe and perform a clinical study. We will then demonstrate the system to the
medical community and begin the commercialization and FDA approval process
while concomitantly completing the design and developing a commercial version
of a clinical prostate imager.
PROPOSED COMMERCIAL APPLICATION: It would be a major commercial opportunity for Imperium to manufacture and market a low cost diagnostic tool for imaging of the prostate. Assuming a per unit price of $25,000, the total US market for this device for prostrate imaging is estimated at $575 Million. The worldwide market is estimated at $1.32 Billion. An approved prostrate diagnostic tool will also pave the way for additional clinical devices, including a low cost speckle free imaging system for breast cancer diagnosis and to use as a biopsy guidance tool.
Technology keywords
Not reported